Fundraising Fox
PharmaCyte Biotech
NASDAQ: PMCBLas Vegas, US · Nevada corporation · 1 known investors
Find your way into PharmaCyte Biotech
Sign up to see every warm intro you have to PharmaCyte Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PharmaCyte Biotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PharmaCyte is a biotechnology company developing Cell-in-a-Box, a live-cell encapsulation technology, to create cellular therapies for cancer, diabetes, and malignant ascites. The company encapsulates genetically engineered human cells to deliver localized drug activation or insulin production.
Founders & leadership
GW
Gerald W CrabtreeExecutive
CA
Carlos A. TrujilloChief Financial Officer
Board
JN
Joshua N. SilvermanCo-Founder and Managing Member (Parkfield Funding LLC)
RW
Robert WeinsteinBoard director
JL
Jonathan L. SchechterBoard director
MM
Michael M. AbecassisBoard director
WR
Walker R. WayneBoard director
TL
Thomas LiquardBoard director
Investors · 1
Also in the syndicate · 1
Existing Investorslead
Reported raises · per SEC filings
Form D private placements$78M disclosed across 3 rounds · 2016–2025
▶$7MraisedSep 2025 · 12 investors · BiotechnologyRule 506(b)
▶$7MraisedSep 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WeinsteinDirector
- Jonathan L. SchechterDirector
- Michael M. AbecassisDirector
- Carlos TrujilloExecutive Officer
- Joshua N. SilvermanExecutive Officer, Director
- Walker R. WayneDirector
- Offering amount
- $7M
- Amount sold
- $7M
- Sales commissions
- $560K
- Placement agents
- GP NURMENKARI INC.
- First sale
- Aug 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$70MraisedSep 2021 · 19 investors · BiotechnologyRule 506(b)
▶$70MraisedSep 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth L. WaggonerExecutive Officer, Director
- Thomas C.K. YuenDirector
- Crabtree W. CrabtreeExecutive Officer, Director
- Michael M. AbecassisDirector
- Raymond CF TongDirector
- Thomas LiquardDirector
- Carlos A. TrujilloExecutive Officer, Director
- Offering amount
- $70M
- Amount sold
- $70M
- Sales commissions
- $5.3M
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Aug 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1MraisedJan 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$1MraisedJan 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gerald W CrabtreeExecutive Officer, Director
- Thomas LiquardDirector
- Kenneth L WaggonerExecutive Officer, Director
- Offering amount
- $3.1M
- Amount sold
- $1M
- Sales commissions
- $30K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Jan 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Incyte CorporationIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as PharmaCyte Biotech.
In the news
Frequently asked questions
- What does PharmaCyte Biotech do?
- PharmaCyte is a biotechnology company developing Cell-in-a-Box, a live-cell encapsulation technology, to create cellular therapies for cancer, diabetes, and malignant ascites. The company encapsulates genetically engineered human cells to deliver localized drug activation or insulin production.
- How much funding has PharmaCyte Biotech raised?
- PharmaCyte Biotech has disclosed $78M raised across 3 rounds.
- Where is PharmaCyte Biotech headquartered?
- PharmaCyte Biotech is headquartered in Las Vegas, US.